BRPI0906786A2 - Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit. - Google Patents

Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.

Info

Publication number: BRPI0906786A2
Authority: BR; Brazil
Prior art keywords: compound; preparing; pharmaceutical composition; kit; disease
Prior art date: 2008-01-18

Application number

BRPI0906786-8A

Other languages

English (en)

Inventor

Richard Edward Armer

Eric Roy Pettipher

Mark Whittaker

Graham Michael Wynne

Julia Vile

Frank Schroer

Original Assignee

Oxagen Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-18

Filing date

2009-01-19

Publication date

2015-07-14

2008-01-18 Priority claimed from GB0800874A external-priority patent/GB0800874D0/en

2008-11-10 Priority claimed from GB0820526A external-priority patent/GB0820526D0/en

2009-01-19 Application filed by Oxagen Ltd filed Critical Oxagen Ltd

2015-07-14 Publication of BRPI0906786A2 publication Critical patent/BRPI0906786A2/pt

2021-10-05 Publication of BRPI0906786B1 publication Critical patent/BRPI0906786B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Virology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)

BRPI0906786-8A 2008-01-18 2009-01-19 Composto, processo para a preparação de um composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, produto BRPI0906786B1 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB0800874A GB0800874D0 (en)	2008-01-18	2008-01-18	Compounds having CRTH2 antagonist activity
GB0800874.0		2008-01-18
GB0820526A GB0820526D0 (en)	2008-11-10	2008-11-10	Compounds having crth2 antagonist activity
GB0820526.2		2008-11-10
PCT/GB2009/000142 WO2009090414A1 (en)	2008-01-18	2009-01-19	Compounds having crth2 antagonist activity

Publications (2)

Publication Number	Publication Date
BRPI0906786A2 true BRPI0906786A2 (pt)	2015-07-14
BRPI0906786B1 BRPI0906786B1 (pt)	2021-10-05

Family

ID=40473418

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0906786-8A BRPI0906786B1 (pt)	2008-01-18	2009-01-19	Composto, processo para a preparação de um composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, produto

Country Status (25)

Country	Link
US (1)	US20090186923A1 (pt)
EP (1)	EP2250161B1 (pt)
JP (2)	JP2011509988A (pt)
KR (1)	KR101644170B1 (pt)
CN (1)	CN101932571B (pt)
AU (1)	AU2009204700B2 (pt)
BR (1)	BRPI0906786B1 (pt)
CA (1)	CA2712017C (pt)
CY (1)	CY1114748T1 (pt)
DK (1)	DK2250161T3 (pt)
ES (1)	ES2442717T3 (pt)
HK (1)	HK1145175A1 (pt)
HR (1)	HRP20140045T1 (pt)
IL (1)	IL206959A (pt)
MA (1)	MA32075B1 (pt)
MX (1)	MX2010007833A (pt)
MY (1)	MY155133A (pt)
NZ (1)	NZ587251A (pt)
PL (1)	PL2250161T3 (pt)
PT (1)	PT2250161E (pt)
RS (1)	RS53142B (pt)
RU (1)	RU2503672C2 (pt)
SI (1)	SI2250161T1 (pt)
WO (1)	WO2009090414A1 (pt)
ZA (1)	ZA201005799B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0324763D0 (en) *	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
WO2009061681A2 (en) *	2007-11-06	2009-05-14	Amira Pharmaceuticals, Inc	Antagonists of pgd2 receptors
US20100280049A1 (en) *	2007-11-06	2010-11-04	Amira Pharmaceuticals, Inc.	Antagonists of pgd2 receptors
US20110124683A1 (en) *	2007-11-13	2011-05-26	Oxagen Limited	Use of CRTH2 Antagonist Compounds
US7750027B2 (en) *	2008-01-18	2010-07-06	Oxagen Limited	Compounds having CRTH2 antagonist activity
DK2250161T3 (da) *	2008-01-18	2014-01-27	Atopix Therapeutics Ltd	Forbindelser med CRTH2-antagonistaktivitet
US20100022613A1 (en) *	2008-01-22	2010-01-28	Oxagen Limited	Compounds Having CRTH2 Antagonist Activity
JP2011509991A (ja) *	2008-01-22	2011-03-31	オキサジェンリミテッド	Ｃｒｔｈ２アンタゴニスト活性を有する化合物
CN101952244B (zh)	2008-02-01	2014-11-05	潘米拉制药公司	前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
US8242145B2 (en) *	2008-02-14	2012-08-14	Panmira Pharmaceuticals, Llc	Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
WO2009108720A2 (en)	2008-02-25	2009-09-03	Amira Pharmaceuticals, Inc.	Antagonists of prostaglandin d2 receptors
US8426449B2 (en) *	2008-04-02	2013-04-23	Panmira Pharmaceuticals, Llc	Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110112134A1 (en) *	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors
US8501959B2 (en) *	2008-06-24	2013-08-06	Panmira Pharmaceuticals, Llc	Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
US8071807B2 (en) *	2008-07-03	2011-12-06	Panmira Pharmaceuticals, Llc	Antagonists of prostaglandin D2 receptors
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en)	2008-10-01	2013-02-19	Panmira Pharmaceuticals, Llc	Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en)	2008-10-08	2013-09-03	Panmira Pharmaceuticals, Llc	Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) *	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en)	2008-11-17	2013-02-26	Panmira Pharmaceuticals, Llc	Heterocyclic antagonists of prostaglandin D2 receptors
SG178109A1 (en) *	2009-07-31	2012-03-29	Panmira Pharmaceuticals Llc	Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
SG10201404662YA (en) *	2009-08-05	2014-10-30	Panmira Pharmaceuticals Llc	Dp2 antagonist and uses thereof
JP2013516475A (ja)	2010-01-06	2013-05-13	アミラファーマシューティカルズ，インク．	Ｄｐ２アンタゴニストおよびその使用
WO2011117798A1 (en)	2010-03-22	2011-09-29	Actelion Pharmaceuticals Ltd	3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
GB201103837D0 (en)	2011-03-07	2011-04-20	Oxagen Ltd	Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
MX338516B (es)	2011-04-14	2016-04-20	Actelion Pharmaceuticals Ltd	Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
WO2013071880A1 (zh) *	2011-11-17	2013-05-23	山东亨利医药科技有限责任公司	作为crth2拮抗剂的含氮并环化合物
GB201121557D0 (en)	2011-12-15	2012-01-25	Oxagen Ltd	Process
AU2012351342A1 (en) *	2011-12-16	2014-07-24	Atopix Therapeutics Limited	Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
ES2600318T3 (es) *	2012-07-10	2017-02-08	F. Hoffmann-La Roche Ag	Nuevos indazoles para el tratamiento y profilaxis de infección por virus sincitial respiratorio
US8815887B2 (en)	2012-12-04	2014-08-26	Millenium Pharmaceuticals, Inc.	Prophylactic or therapeutic method for Sjogren's syndrome
AU2014235273A1 (en) *	2013-03-14	2015-07-09	Celgene Corporation	Treatment of psoriatic arthritis using apremilast
GB201322273D0 (en) *	2013-12-17	2014-01-29	Atopix Therapeutics Ltd	Process
ES2900426T3 (es) *	2013-12-31	2022-03-16	Rapamycin Holdings Llc	Preparaciones orales y uso de nanopartículas de rapamicina
MA39750B1 (fr)	2014-03-17	2018-12-31	Idorsia Pharmaceuticals Ltd	Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
TW201620909A (zh)	2014-03-18	2016-06-16	艾克泰聯製藥有限公司	氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途
GB201407813D0 (en) *	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
GB201407807D0 (en) *	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
GB201407820D0 (en) *	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
KR102343802B1 (ko) *	2014-06-09	2021-12-28	수미토모 케미칼 컴퍼니 리미티드	피리딘 화합물의 제조 방법
EP3188745A1 (en)	2014-08-15	2017-07-12	Celgene Corporation	Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
EP3350179B1 (en)	2015-09-15	2021-01-13	Idorsia Pharmaceuticals Ltd	Crystalline forms
AU2018318075B2 (en)	2017-08-14	2023-04-13	Allergan, Inc.	3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
WO2020143793A1 (zh) *	2019-01-10	2020-07-16	石药集团中奇制药技术（石家庄）有限公司	杂环化合物盐及其应用
CN114796264A (zh) *	2021-01-27	2022-07-29	北京北工大科技园有限公司	金络合物在制备治疗新型冠状病毒肺炎的药物中的应用
CA3182036A1 (en) *	2020-06-12	2021-12-16	Nucmito Pharmaceuticals Co., Ltd.	Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
US12102622B2 (en)	2021-02-10	2024-10-01	Iolyx Therapeutics, Inc.	Methods for ophthalmic delivery of roflumilast
CA3218813A1 (en) *	2021-05-15	2022-11-24	Nucmito Pharmaceuticals Company Limited	Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
CN115192584A (zh) *	2022-06-09	2022-10-18	南方科技大学	一种纳米药物及其制备方法和应用
WO2024104384A1 (en) *	2022-11-16	2024-05-23	Nucmito Pharmaceuticals Co. Ltd.	Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3557142A (en)	1968-02-20	1971-01-19	Sterling Drug Inc	4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
BE790679A (fr)	1971-11-03	1973-04-27	Ici Ltd	Derives de l'indole
GB1407658A (en)	1973-03-06	1975-09-24	Ici Ltd	Process for the manufacture of indole derivatives
GB1460348A (en)	1974-02-04	1977-01-06	Ici Ltd	Quinazoline derivativesa
DK151884C (da)	1979-03-07	1988-06-13	Pfizer	Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4363912A (en) *	1980-12-15	1982-12-14	Pfizer Inc.	Indole thromboxane synthetase inhibitors
GB8607294D0 (en)	1985-04-17	1986-04-30	Ici America Inc	Heterocyclic amide derivatives
GB9122590D0 (en)	1991-10-24	1991-12-04	Lilly Industries Ltd	Pharmaceutical compounds
EP0851030B9 (en)	1996-06-05	2007-10-31	BML Inc.	PROTEIN SPECIFIC TO HUMAN Th2, GENE (B19) ENCODING THE SAME, AND TRANSFORMANT, RECOMBINANT VECTOR AND MONOCLONAL ANTIBODY RELATING THERETO
US6916841B2 (en)	1998-02-25	2005-07-12	Genetics Institute, Llc	Inhibitors of phospholipase enzymes
TR200002869T2 (tr)	1998-03-31	2000-12-21	The Institute For Pharmaceutical Discovery,Inc.	İkame edilmiş indolealkonik asitler.
TNSN99224A1 (fr)	1998-12-01	2005-11-10	Inst For Pharm Discovery Inc	Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB9902461D0 (en) *	1999-02-05	1999-03-24	Zeneca Ltd	Chemical compounds
CA2383135C (en)	1999-08-23	2010-11-30	Hiroyuki Hirai	Method of identifying properties of substance with respect to human prostaglandin d2 receptors
CN1145753C (zh)	2000-01-14	2004-04-14	皇家菲利浦电子有限公司	显示装置
US6521659B2 (en)	2000-03-02	2003-02-18	Institute For Pharmaceutical Discovery, Llc	Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
JP2001247570A (ja)	2000-03-08	2001-09-11	Japan Tobacco Inc	インドール酢酸化合物及びその製造方法
US6878522B2 (en)	2000-07-07	2005-04-12	Baiyong Li	Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
SE0200356D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
EP2423190A1 (en)	2002-05-16	2012-02-29	Shionogi&Co., Ltd.	Compounds Exhibiting PGD 2 Receptor Antagonism
JPWO2003097042A1 (ja)	2002-05-16	2005-09-15	塩野義製薬株式会社	Ｐｇｄ２受容体拮抗剤
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
TW200307542A (en)	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
US7364647B2 (en)	2002-07-17	2008-04-29	Eksigent Technologies Llc	Laminated flow device
SE0202241D0 (sv) *	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
CA2511214C (en)	2002-12-20	2012-12-18	Tularik, Inc.	Asthma and allergic inflammation modulators
JP4324418B2 (ja)	2003-08-05	2009-09-02	株式会社日立国際電気	基板処理装置および半導体デバイスの製造方法
SE0302232D0 (sv)	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
RU2006109108A (ru) *	2003-10-14	2007-11-20	Оксаген Лимитед (GB)	Соединения, обладающие активностью антагонистов crth2 рецепторов
GB0324763D0 (en) *	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
US7897788B2 (en)	2004-03-11	2011-03-01	Actelion Pharmaceutical Ltd.	Indol-1-yl-acetic acid derivatives
MXPA06011891A (es) *	2004-04-20	2007-04-24	Pfizer	Metodo para tratar el dolor neuropatico.
MX2007003336A (es)	2004-09-21	2007-06-05	Athersys Inc	Acidos aceticos de indol que muestran antagonismo de receptor crth2 y usos de los mismos.
GB0504150D0 (en)	2005-03-01	2005-04-06	Oxagen Ltd	Microcrystalline material
GB0505048D0 (en) *	2005-03-11	2005-04-20	Oxagen Ltd	Compounds with PGD antagonist activity
PL65781Y1 (pl)	2005-08-16	2012-02-29	Katarzyna Kawczyńska	Wkładka kosmetyczna
NZ574375A (en)	2006-07-22	2011-06-30	Oxagen Ltd	2-(5-fluoro-2-methyI-3-(2-(phenylsulfonyl)benzyl)-1H-indol-1-yl) acetic acid derivatives having CRTH2 antagonist activity
GB0722203D0 (en) *	2007-11-13	2007-12-19	Oxagen Ltd	Use of CRTH2 antagonist compounds
DK2327693T3 (da) *	2007-12-14	2012-08-13	Pulmagen Therapeutics Asthma Ltd	Indoler og terapeutisk anvendelse deraf
DK2250161T3 (da) *	2008-01-18	2014-01-27	Atopix Therapeutics Ltd	Forbindelser med CRTH2-antagonistaktivitet

2009
- 2009-01-19 DK DK09702598.5T patent/DK2250161T3/da active
- 2009-01-19 RU RU2010129027/04A patent/RU2503672C2/ru active
- 2009-01-19 PL PL09702598T patent/PL2250161T3/pl unknown
- 2009-01-19 RS RS20140016A patent/RS53142B/en unknown
- 2009-01-19 EP EP09702598.5A patent/EP2250161B1/en active Active
- 2009-01-19 ES ES09702598.5T patent/ES2442717T3/es active Active
- 2009-01-19 KR KR1020107017661A patent/KR101644170B1/ko active IP Right Grant
- 2009-01-19 JP JP2010542688A patent/JP2011509988A/ja active Pending
- 2009-01-19 WO PCT/GB2009/000142 patent/WO2009090414A1/en active Application Filing
- 2009-01-19 PT PT97025985T patent/PT2250161E/pt unknown
- 2009-01-19 MX MX2010007833A patent/MX2010007833A/es active IP Right Grant
- 2009-01-19 CN CN200980103456.8A patent/CN101932571B/zh not_active Expired - Fee Related
- 2009-01-19 BR BRPI0906786-8A patent/BRPI0906786B1/pt not_active IP Right Cessation
- 2009-01-19 MY MYPI2010003390A patent/MY155133A/en unknown
- 2009-01-19 SI SI200930822T patent/SI2250161T1/sl unknown
- 2009-01-19 AU AU2009204700A patent/AU2009204700B2/en not_active Ceased
- 2009-01-19 NZ NZ587251A patent/NZ587251A/en not_active IP Right Cessation
- 2009-01-19 CA CA2712017A patent/CA2712017C/en active Active
- 2009-01-21 US US12/356,822 patent/US20090186923A1/en not_active Abandoned
2010
- 2010-07-12 IL IL206959A patent/IL206959A/en active IP Right Grant
- 2010-08-13 ZA ZA2010/05799A patent/ZA201005799B/en unknown
- 2010-08-13 MA MA33081A patent/MA32075B1/fr unknown
- 2010-12-14 HK HK10111663.1A patent/HK1145175A1/xx not_active IP Right Cessation
2014
- 2014-01-15 HR HRP20140045AT patent/HRP20140045T1/hr unknown
- 2014-01-15 CY CY20141100031T patent/CY1114748T1/el unknown
- 2014-05-07 JP JP2014095946A patent/JP5855162B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
RS53142B (en)	2014-06-30
JP5855162B2 (ja)	2016-02-09
CN101932571B (zh)	2014-04-23
CN101932571A (zh)	2010-12-29
ES2442717T3 (es)	2014-02-13
DK2250161T3 (da)	2014-01-27
JP2014159465A (ja)	2014-09-04
IL206959A (en)	2014-09-30
US20090186923A1 (en)	2009-07-23
CY1114748T1 (el)	2016-12-14
BRPI0906786B1 (pt)	2021-10-05
PL2250161T3 (pl)	2014-05-30
RU2010129027A (ru)	2012-02-27
KR101644170B1 (ko)	2016-08-01
MX2010007833A (es)	2010-08-11
NZ587251A (en)	2011-12-22
SI2250161T1 (sl)	2014-04-30
WO2009090414A1 (en)	2009-07-23
HRP20140045T1 (hr)	2014-02-14
RU2503672C2 (ru)	2014-01-10
PT2250161E (pt)	2014-01-21
EP2250161A1 (en)	2010-11-17
CA2712017C (en)	2016-08-09
KR20100110361A (ko)	2010-10-12
AU2009204700B2 (en)	2013-07-04
IL206959A0 (en)	2010-12-30
AU2009204700A1 (en)	2009-07-23
MY155133A (en)	2015-09-15
EP2250161B1 (en)	2013-10-16
HK1145175A1 (en)	2011-04-08
MA32075B1 (fr)	2011-02-01
ZA201005799B (en)	2012-01-25
JP2011509988A (ja)	2011-03-31
CA2712017A1 (en)	2009-07-23

Publication	Publication Date	Title
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI1009022A2 (pt)	2016-03-08	"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0921687A2 (pt)	2015-08-18	Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BRPI0612109A2 (pt)	2016-09-06	composto, métodos de tratamento ou prevenção de uma doença, formulação farmacêutica, e, processo para preparar um composto
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BR112013013435A2 (pt)	2016-10-11	composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto.
BR122020011920A2 (pt)	2020-08-25	composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0913585A2 (pt)	2015-10-27	composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0912348A2 (pt)	2015-10-13	composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BRPI0911685A2 (pt)	2015-10-13	composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0820578A2 (pt)	2015-06-16	Vírus da varíola, processo para preparar um vírus da varíola, composição, uso de um vírus da varíola ou de uma composição, e, método para tratar doenças
BR112012029227A2 (pt)	2016-11-29	processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0818533A2 (pt)	2017-06-06	composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0907974A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.

Legal Events

Date	Code	Title	Description
2017-06-27	B25G	Requested change of headquarter approved	Owner name: OXAGEN LIMITED (GB)
2017-07-18	B25A	Requested transfer of rights approved	Owner name: ATOPIX THERAPEUTICS LIMITED (GB)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-07	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-08-04	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-04-27	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-08-10	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-10-05	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/01/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2023-11-14	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 15A ANUIDADE.
2024-03-05	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2758 DE 14-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.